Table 3.

Hierarchical and non-hierarchical subject counts of adverse events through 12 months (intent-to-treat population)

n (%)	30 days	6 months	12 months
Hierarchical events
TLF	2 (0.4)	8 (1.7)	11 (2.4)
Cardiac death	1 (0.2)	3 (0.6)	4 (0.9)
Target-vessel MI	1 (0.2)	3 (0.6)	3 (0.6)
Target-lesion revascularisation	0 (0)	5 (1.1)	7 (1.5)
Target vessel failure	2 (0.4)	11 (2.4)	14 (3.0)
Major adverse cardiovascular events	4 (0.9)	14 (3.0)	18 (3.9)
Non-hierarchical events
Death	1 (0.2)	1 (0.2)	6 (1.3)
Cardiac death	1 (0.2)	3 (0.6)	4 (0.9)
Non-cardiac death	0 (0.0)	1 (0.2)	2 (0.4)
Myocardial infarction
Target vessel	1 (0.2)	3 (0.6)	3 (0.6)
Non-target vessel	2 (0.4)	3 (0.6)	4 (0.9)
Revascularisation
Target lesion revascularisation	1 (0.2)	5 (1.1)	7 (1.5)
Target vessel revascularisation	1 (0.2)	10 (2.2)	14 (3.0)
Non target vessel revascularisation	2 (0.4)	4 (0.8)	6 (1.2)
Stent thrombosis	1 (0.2)	3 (0.6)	4 (0.9)
Definite ST	0 (0.0)	0 (0.0)	0 (0.0)
Probable ST	1 (0.2)	1 (0.2)	1 (0.2)
Possible ST	0 (0.0)	2 (0.4)	3 (0.6)

MACE, major adverse cardiac events (composite of cardiac death, any MI, emergent or repeat revascularisation); MI, myocardial Infarction; ST, stent thrombosis; TLF, target lesion failure (composite of cardiac death, target vessel MI or clinically driven TLR); TVF, target vessel failure (composite of cardiac death, target vessel MI and TVR); TVR, target vessel revascularisation.